<!-- librarian dossier written 2026-10-16; every sentence cites its source; lint-clean; figures cross-checked against the cited SEC documents -->
# ELV — Elevance Health, Inc. — dossier 2026-10-16

Worklist reason: insider score moved 54.0 -> 0.0; CIK 0001156039, NYSE, SIC 6324 Hospital & Medical Service Plans, Indiana, fiscal year end December 31, flagged is_financial in the stock record. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)

## 1. Business

Elevance Health describes itself as one of the largest health insurers in the United States by medical membership, serving approximately 45.2 million medical members through its affiliated health plans as of December 31, 2025. [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
It offers network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets, and managed care services to fee-based customers such as claims processing, stop loss insurance, provider network access and medical management. [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
The Company is an independent licensee of the Blue Cross and Blue Shield Association, serving as the Blue Cross licensee for California and the BCBS licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (in part), Nevada, New Hampshire, New York (in part), Ohio, Virginia (in part) and Wisconsin. [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
Its core go-to-market brands are Anthem Blue Cross/Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon (CarelonRx and Carelon Services). [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
It reports four segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other. [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
The filing states that approximately 32%, 31% and 29% of total consolidated revenues came from agencies of the U.S. government for 2025, 2024 and 2023 respectively. [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C., a CVS Health subsidiary, under an agreement with a current term through December 31, 2027 (paraphrased). [10-K FY2025 Item 1](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
The Company leases its principal executive offices at 220 Virginia Avenue, Indianapolis, Indiana. [10-K FY2025 Item 2](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)

## 2. Capital structure

The unaudited consolidated balance sheet at June 30, 2026 (USD millions) shows cash and cash equivalents of 10,232, total current assets of 67,184, goodwill of 28,339 and total assets of 126,438. [10-Q Q2 2026 balance sheet](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Current liabilities total 44,254, including medical claims payable of 18,463, no short-term borrowings (150 at December 31, 2025) and current portion of long-term debt of 375. [10-Q Q2 2026 balance sheet](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Long-term debt less current portion is 30,669, total liabilities are 81,416, total shareholders' equity is 44,883 and total equity including noncontrolling interests is 45,022. [10-Q Q2 2026 balance sheet](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Shares issued and outstanding were 216,841,146 at June 30, 2026 and 220,723,898 at December 31, 2025, and the cover page reports 216,869,290 shares outstanding as of July 10, 2026. [10-Q Q2 2026](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Note 9 lists senior unsecured notes of 31,019 and an unsecured surplus note of 25, for total long-term debt of 31,044 at June 30, 2026 (31,896 at December 31, 2025). [10-Q Q2 2026 Note 9](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
On March 15, 2026 the Company repaid at maturity the 750 outstanding balance of its 1.500% senior unsecured notes. [10-Q Q2 2026 Note 9](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Short-term facilities are a 5-Year revolving credit facility providing credit of 5,000 maturing September 2030, a commercial paper program of up to 5,000, and FHLB borrowing arrangements, with nothing drawn on any of them at June 30, 2026. [10-Q Q2 2026 Note 9](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Note 9 states the Company was in compliance with its debt covenants as of June 30, 2026. [10-Q Q2 2026 Note 9](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
Six-month 2026 total revenues were 100,655 and diluted shareholders' EPS was 14.73, against 98,667 and 17.33 in the 2025 period. [10-Q Q2 2026 statements of income](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)

## 3. Earnings record

Values below are the stock JSON net_income_by_fy, eps_diluted_by_fy and revenue_by_fy arrays; the cross-check column records a comparison against SEC XBRL companyfacts made in this run. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)

| FY | Net income (USD) | Diluted EPS | Revenue (USD) | Companyfacts cross-check | Source |
|---|---|---|---|---|---|
| 2016 | 2,470,000,000 | 9.21 | 84,863,000,000 | match (companyfacts also carries 2,469,800,000) | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2017 | 3,843,000,000 | 14.35 | 90,040,000,000 | match (companyfacts also carries 3,842,800,000 and revenue 90,039,400,000) | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2018 | 3,750,000,000 | 14.19 | 92,105,000,000 | match | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2019 | 4,807,000,000 | 18.47 | 104,213,000,000 | match | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2020 | 4,572,000,000 | 17.98 | 121,867,000,000 | match | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2021 | 6,158,000,000 | 24.95 | 138,639,000,000 | match to later filings; original FY2021 10-K tagged 6,104,000,000 and EPS 24.73 | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2022 | 5,894,000,000 | 24.28 | 156,595,000,000 | match to later filings; original FY2022 10-K tagged 6,025,000,000 and EPS 24.81 | [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json) |
| 2023 | 5,987,000,000 | 25.22 | 171,340,000,000 | match; 10-K FY2025 shows 5,987 million and 25.22 | [10-K FY2025](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm) |
| 2024 | 5,980,000,000 | 25.68 | 177,011,000,000 | match; 10-K FY2025 shows 5,980 million and 25.68 | [10-K FY2025](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm) |
| 2025 | 5,662,000,000 | 25.21 | 199,125,000,000 | match; 10-K FY2025 shows 5,662 million and 25.21 | [10-K FY2025](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm) |

The FY2025 10-K reports shareholders' net income of $5,662 million for 2025, $5,980 million for 2024 and $5,987 million for 2023, and net income including noncontrolling interests of $5,661 million, $5,971 million and $5,991 million. [10-K FY2025 Item 8](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
The JSON also holds FY2013 to FY2015 figures (net income 2,489,700,000; 2,569,700,000; 2,560,000,000), outside the ten-year window, and these match companyfacts. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)
The JSON dividend_years array lists every year from 2011 through 2026. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)

## 4. Recent filings

8-K filings dated 2026-04-19 to 2026-10-16 per the EDGAR submissions feed are listed below, one line each. [EDGAR submissions](https://data.sec.gov/submissions/CIK0001156039.json)

- 2026-09-10, Item 7.01: "During these meetings, Company officers ... reaffirm the Company's shareholders' earnings guidance for full year 2026 to be at least $20.10 per diluted share, including approximately $6.90 per diluted share of net unfavorable items." [8-K 2026-09-10](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000063/elv-20260910.htm)
- 2026-07-15, Items 2.02 / 9.01: "On July 15, 2026, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2026." [8-K 2026-07-15](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000058/elv-20260715.htm)
- 2026-06-10, Item 7.01: "During these meetings, Company officers ... reaffirm the Company's shareholders' earnings guidance for full year 2026 to be at least $19.85 per diluted share, including approximately $6.90 per diluted share of net unfavorable items." [8-K 2026-06-10](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000049/elv-20260610.htm)
- 2026-05-13, Item 5.07: "There were 194,441,339 shares of common stock represented at the Annual Meeting, constituting a quorum"; directors Gail K. Boudreaux, Robert L. Dixon, Jr. and Deanna D. Strable were elected, say-on-pay and the Ernst & Young ratification were approved, and a shareholder proposal on 527 political contributions was not approved. [8-K 2026-05-13](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000046/elv-20260513.htm)
- 2026-04-22, Items 2.02 / 9.01: "On April 22, 2026, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026." [8-K 2026-04-22](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000039/elv-20260422.htm)

Periodic filings in the window: 10-Q for the quarter ended March 31, 2026 filed 2026-04-22 and 10-Q for the quarter ended June 30, 2026 filed 2026-07-15. [EDGAR submissions](https://data.sec.gov/submissions/CIK0001156039.json)

## 5. Insiders

Form 4 filings dated 2025-10-16 to 2026-10-16 per the submissions feed were parsed; open-market purchases (P), sales (S) and option exercises (M) are in the first table, and grants, tax withholding and option awards in the second. [EDGAR submissions](https://data.sec.gov/submissions/CIK0001156039.json)

| Txn date | Reporting owner | Role | Code | Shares | Price (USD) | Owned after | D/I | 10b5-1 box | 10b5-1 footnote | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-17 | PERU RAMIRO G | Director | P | 1,000 | 366.05 | 10,908 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000119204526000004/wk-form4_1784315092.xml) |
| 2026-07-17 | BOUDREAUX GAIL | Director; President and CEO | P | 680 | 366.41 | 169,931 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000128792026000006/wk-form4_1784310641.xml) |
| 2026-07-17 | BOUDREAUX GAIL | Director; President and CEO | P | 2,045 | 368.25 | 171,976 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000128792026000006/wk-form4_1784310641.xml) |
| 2026-06-12 | Penczek Ronald W | CAO & Controller | S | 369 | 403.16 | 3,740 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000006/wk-form4_1781554242.xml) |
| 2026-06-11 | Dixon Robert L JR | Director | S | 151 | 401.77 | 10,734 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000152484926000004/wk-form4_1781295167.xml) |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | M | 654 | 271.27 | 4,763 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000004/wk-form4_1779307888.xml) |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | M | 877 | 311.48 | 5,640 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000004/wk-form4_1779307888.xml) |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | S | 1,531 | 403.13 | 4,109 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000004/wk-form4_1779307888.xml) |
| 2026-03-12 | SCHULMAN AMY W | Director | S | 26 | 287.5 | 218 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000143822626000007/wk-form4_1774296634.xml) |
| 2026-03-06 | Kendrick Charles Morgan JR | EVP & President, Commercial | S | 3,196 | 284.92 | 11,791 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000188790826000005/wk-form4_1773089106.xml) |
| 2026-03-05 | COLLIS STEVEN H | Director | P | 3,000 | 289.84 | 3,639 | D | 0 | none in footnotes | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000119150826000002/wk-form4_1772802204.xml) |

| Period | Reporting owner | Role | Non-open-market transactions (code, shares, price) | Source |
|---|---|---|---|---|
| 2026-10-02 | Kaye Mark | EVP & CFO | F 4,161 at 386.43; A 2,627 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000174869126000005/wk-form4_1791316964.xml) |
| 2026-09-02 | Wessling Erin M | EVP & Chief Legal Officer | F 94 at 405.84; F 255 at 414.78 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000208454826000005/wk-form4_1788552374.xml) |
| 2026-09-02 | Craig Ryan R | EVP & Chief HR Officer | F 144 at 405.84 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000208454726000009/wk-form4_1788552323.xml) |
| 2026-05-19 | Penczek Ronald W | CAO & Controller | M 654 (Employee Stock Option (Right to Buy)); M 877 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000004/wk-form4_1779307888.xml) |
| 2026-05-13 | STRABLE-SOETHOUT DEANNA D | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000162828026035643/wk-form4_1778877227.xml) |
| 2026-05-13 | SCHULMAN AMY W | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000143822626000009/wk-form4_1778876180.xml) |
| 2026-05-13 | Schneider Ryan M. | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000142050126000004/wk-form4_1778876145.xml) |
| 2026-05-13 | PERU RAMIRO G | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000119204526000002/wk-form4_1778876111.xml) |
| 2026-05-13 | Neri Antonio F | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000164840126000006/wk-form4_1778876082.xml) |
| 2026-05-13 | Jallal Bahija | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000173003826000004/wk-form4_1778876036.xml) |
| 2026-05-13 | HAY LEWIS III | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000118270526000004/wk-form4_1778875959.xml) |
| 2026-05-13 | Dixon Robert L JR | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000152484926000002/wk-form4_1778875932.xml) |
| 2026-05-13 | DeVore Susan D. | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000158769726000006/wk-form4_1778875890.xml) |
| 2026-05-13 | COLLIS STEVEN H | Director | A 563 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000119150826000004/wk-form4_1778875844.xml) |
| 2026-03-02 | Penczek Ronald W | CAO & Controller | F 131 at 294.07; A 426; A 1,701; A 266; F 37 at 284.03; A 1,677 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000002/wk-form4_1772661603.xml) |
| 2026-03-02 | Wessling Erin M | EVP & Chief Legal Officer | A 2,976; F 417 at 284.03; A 11,754 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000208454826000002/wk-form4_1772661583.xml) |
| 2026-03-02 | Craig Ryan R | EVP & Chief HR Officer | F 25 at 294.07; A 2,976; F 309 at 284.03; A 11,754 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000208454726000005/wk-form4_1772661549.xml) |
| 2026-03-02 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | F 1,421 at 294.07; A 5,951; A 2,865; F 496 at 284.03; A 23,512 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000174354826000002/wk-form4_1772661524.xml) |
| 2026-03-02 | LAVU RATNAKAR | EVP & Chief Digital Info Ofr | F 315 at 294.07; A 5,101; A 6,802; F 222 at 284.03; A 20,152 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000173762026000002/wk-form4_1772661505.xml) |
| 2026-03-02 | Kendrick Charles Morgan JR | EVP & President, Commercial | F 1,211 at 294.07; A 4,017; A 2,532; F 467 at 284.03; A 15,870 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000188790826000002/wk-form4_1772661487.xml) |
| 2026-03-02 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | F 1,201 at 294.07; A 2,865; F 446 at 284.03 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000160853826000002/wk-form4_1772661470.xml) |
| 2026-03-02 | Kaye Mark | EVP & CFO | F 271 at 294.07; A 6,377; A 10,202; F 353 at 284.03; A 25,188 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000174869126000002/wk-form4_1772661447.xml) |
| 2026-03-02 | BOUDREAUX GAIL | Director; President and CEO | F 6,713 at 294.07; A 16,153; A 10,527; F 1,736 at 284.03; A 63,818 (Employee Stock Option (Right to Buy)) | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000128792026000002/wk-form4_1772661402.xml) |
| 2026-02-02 | SCHULMAN AMY W | Director | A 218 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000143822626000005/wk-form4_1770154954.xml) |
| 2026-02-02 | Craig Ryan R | EVP & Chief HR Officer | F 279 at 341.83 | [Form 4](https://www.sec.gov/Archives/edgar/data/1156039/000208454726000003/wk-form4_1770153318.xml) |

No Form 4 in the period checks the Rule 10b5-1 box (all report 0), and no footnote in the parsed Form 4s cites a Rule 10b5-1 plan. [EDGAR Form 4 list](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001156039&type=4)
No private placement or unregistered sale appears in the 8-K filings of the 180-day window. [EDGAR submissions](https://data.sec.gov/submissions/CIK0001156039.json)
Gail Boudreaux's Form 4 reports purchases of 680 shares at a weighted average $366.41 and 2,045 shares at a weighted average $368.25 on 2026-07-17, executed in multiple purchases at prices ranging from $366.14 to $368.69 per the footnotes. [Form 4 Boudreaux](https://www.sec.gov/Archives/edgar/data/1156039/000128792026000006/wk-form4_1784310641.xml)
Ramiro G. Peru's Form 4 reports a purchase of 1,000 shares at $366.05 on 2026-07-17, leaving 10,908 shares held directly. [Form 4 Peru](https://www.sec.gov/Archives/edgar/data/1156039/000119204526000004/wk-form4_1784315092.xml)
The insider score coverage block reads window_start 2026-07-18 through 2026-10-14, status "no open-market transactions in window", with zero distinct buyers. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)
The three 2026-07-17 purchases carry a transaction date one day before that window_start, and the only Form 4 transactions dated inside the window are code F tax withholdings (2026-09-02, 2026-09-03, 2026-10-02) and one code A award (2026-10-02). [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)
The filings therefore show the move from 54.0 to 0.0 coinciding with the 2026-07-17 purchases leaving the scoring window, with no new open-market purchase or sale reported since. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)

## 6. Data health

The Graham and Magic Formula blocks are "not scored (financial)" / "not scored" with empty input lists, so no input in the JSON carries a mismatch or unverified status. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)
The momentum input (adjusted close series) has a null source URL, and the insider block has an empty inputs list with verification null. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)
JSON price 428.43 as of 2026-10-15 agrees with the Yahoo chart API close of 428.43 for 2026-10-15. [Yahoo quote](https://finance.yahoo.com/quote/ELV)
The JSON share count used for market cap (216,869,290 at 2026-07-10) agrees with the 10-Q cover page figure of 216,869,290 shares as of July 10, 2026. [10-Q Q2 2026 cover](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
The sec_shares_outstanding URL in the JSON points to the accession folder rather than to the primary document elv-20260630.htm. [site/s/ELV.json](https://theclaudetrader.com/s/ELV.json)
FY2021 and FY2022 net income and EPS in the JSON are the values tagged in later 10-K filings, while the original FY2021 and FY2022 10-Ks tagged different values (6,104,000,000 / 24.73 and 6,025,000,000 / 24.81). [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json)
All six insider_transactions_recent entries agree with the Form 4 share counts and prices, and the Penczek 2026-05-19 sale of 1,531 shares followed same-day option exercises of 654 and 877 shares reported on the same Form 4. [Form 4 Penczek](https://www.sec.gov/Archives/edgar/data/1156039/000165907526000004/wk-form4_1779307888.xml)
The Steven H. Collis purchase of 3,000 shares at $289.84 on 2026-03-05 appears in the Form 4 record but not in insider_transactions_recent, whose earliest entry is dated 2026-05-19. [Form 4 Collis](https://www.sec.gov/Archives/edgar/data/1156039/000119150826000002/wk-form4_1772802204.xml)
The JSON exchange field (NYSE) agrees with the 8-K cover pages. [8-K 2026-07-15](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000058/elv-20260715.htm)

## 7. Agent log

2026-10-16 05:57 CEST: fetched EDGAR submissions JSON for CIK 0001156039 with the declared user agent. [EDGAR submissions](https://data.sec.gov/submissions/CIK0001156039.json)
2026-10-16 06:01 CEST: fetched the FY2025 10-K primary document and read Item 1, Item 2 and the Item 7/Item 8 income tables. [10-K FY2025](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000013/elv-20251231.htm)
2026-10-16 06:01 CEST: fetched the Q2 2026 10-Q primary document and read the cover, balance sheet, statements of income and Note 9. [10-Q Q2 2026](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm)
2026-10-16 06:01 CEST: fetched five 8-Ks (2026-04-22, 2026-05-13, 2026-06-10, 2026-07-15, 2026-09-10) and read the item text. [EDGAR 8-K list](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001156039&type=8-K)
2026-10-16 06:01 CEST: fetched and parsed 32 Form 4 XML documents filed 2026-02-03 to 2026-10-06, including footnotes and the Rule 10b5-1 checkbox. [EDGAR Form 4 list](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001156039&type=4)
2026-10-16 06:02 CEST: fetched XBRL companyfacts and compared NetIncomeLoss, EarningsPerShareDiluted and Revenues facts to the JSON arrays. [companyfacts](https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json)
2026-10-16 06:04 CEST: fetched Yahoo chart API 5-day closes for ELV. [Yahoo quote](https://finance.yahoo.com/quote/ELV)
Not reached: 8-K exhibit 99.1 press releases, the proposed-sale notices (Form-144 filings), the Q1 2026 10-Q, the DEF 14A of 2026-03-27, and the FY2025 10-K debt footnote (Note 13). [EDGAR filing index](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001156039)